Cargando…
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
Small cell lung cancer (SCLC) is a very aggressive disease, characterised by rapid growth, high response rates to both chemotherapy and radiotherapy and subsequent development of treatment resistance in the vast majority of patients. In the past 30 years, little progress has been made in systemic tr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070242/ https://www.ncbi.nlm.nih.gov/pubmed/27843619 http://dx.doi.org/10.1136/esmoopen-2015-000022 |
_version_ | 1782461104841031680 |
---|---|
author | Paglialunga, Luca Salih, Zena Ricciuti, Biagio Califano, Raffaele |
author_facet | Paglialunga, Luca Salih, Zena Ricciuti, Biagio Califano, Raffaele |
author_sort | Paglialunga, Luca |
collection | PubMed |
description | Small cell lung cancer (SCLC) is a very aggressive disease, characterised by rapid growth, high response rates to both chemotherapy and radiotherapy and subsequent development of treatment resistance in the vast majority of patients. In the past 30 years, little progress has been made in systemic treatments and the established management paradigm of platinum-based chemotherapy has reached an efficacy plateau. Several clinical trials have investigated targeted therapies, without producing clinically significant benefits. Recently presented early phase clinical trials with immune checkpoint inhibitors (blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and blockade of the programmed cell death-1 (PD-1) receptor) have shown promising results. In this review, we present the emerging evidence on immune checkpoint blockade for SCLC. |
format | Online Article Text |
id | pubmed-5070242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50702422016-11-14 Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? Paglialunga, Luca Salih, Zena Ricciuti, Biagio Califano, Raffaele ESMO Open Review Small cell lung cancer (SCLC) is a very aggressive disease, characterised by rapid growth, high response rates to both chemotherapy and radiotherapy and subsequent development of treatment resistance in the vast majority of patients. In the past 30 years, little progress has been made in systemic treatments and the established management paradigm of platinum-based chemotherapy has reached an efficacy plateau. Several clinical trials have investigated targeted therapies, without producing clinically significant benefits. Recently presented early phase clinical trials with immune checkpoint inhibitors (blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and blockade of the programmed cell death-1 (PD-1) receptor) have shown promising results. In this review, we present the emerging evidence on immune checkpoint blockade for SCLC. BMJ Publishing Group 2016-08-05 /pmc/articles/PMC5070242/ /pubmed/27843619 http://dx.doi.org/10.1136/esmoopen-2015-000022 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review Paglialunga, Luca Salih, Zena Ricciuti, Biagio Califano, Raffaele Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? |
title | Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? |
title_full | Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? |
title_fullStr | Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? |
title_full_unstemmed | Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? |
title_short | Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? |
title_sort | immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070242/ https://www.ncbi.nlm.nih.gov/pubmed/27843619 http://dx.doi.org/10.1136/esmoopen-2015-000022 |
work_keys_str_mv | AT paglialungaluca immunecheckpointblockadeinsmallcelllungcanceristherealightattheendofthetunnel AT salihzena immunecheckpointblockadeinsmallcelllungcanceristherealightattheendofthetunnel AT ricciutibiagio immunecheckpointblockadeinsmallcelllungcanceristherealightattheendofthetunnel AT califanoraffaele immunecheckpointblockadeinsmallcelllungcanceristherealightattheendofthetunnel |